402 related articles for article (PubMed ID: 24709415)
1. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
Culp SH; Karam JA; Wood CG
Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
4. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
5. Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.
Sun M; Bianchi M; Hansen J; Abdollah F; Trinh QD; Lughezzani G; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
Int J Urol; 2013 Apr; 20(4):372-80. PubMed ID: 23039208
[TBL] [Abstract][Full Text] [Related]
6. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study.
Capitanio U; Zini L; Perrotte P; Shariat SF; Jeldres C; Arjane P; Pharand D; Widmer H; Péloquin F; Montorsi F; Patard JJ; Karakiewicz PI
Urology; 2008 Nov; 72(5):1090-5. PubMed ID: 18799207
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
10. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
11. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?
Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T
Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834
[TBL] [Abstract][Full Text] [Related]
14. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
15. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: a single-center retrospective study.
Antonelli A; Arrighi N; Corti S; Zanotelli T; Cozzoli A; Cosciani Cunico S; Simeone C
Urol Oncol; 2013 Oct; 31(7):1310-5. PubMed ID: 22281433
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
18. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
[TBL] [Abstract][Full Text] [Related]
19. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Conti SL; Thomas IC; Hagedorn JC; Chung BI; Chertow GM; Wagner TH; Brooks JD; Srinivas S; Leppert JT
Int J Cancer; 2014 May; 134(9):2245-52. PubMed ID: 24135850
[TBL] [Abstract][Full Text] [Related]
20. Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database.
Daugherty M; Bratslavsky G
Urol Oncol; 2014 Jul; 32(5):549-54. PubMed ID: 24495447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
